Some Investors Are Against the CoreWeave-Core Scientific Deal. Here's Why That Matters.

Institutional Shareholder Services (ISS) has recommended Core Scientific shareholders reject CoreWeave's proposed $9 billion all-stock acquisition, asserting that Core Scientific is now undervalued given the increased market appetite for AI-related investments since the July offer. This recommendation prompted a nearly 3% rise in Core Scientific shares and a decline in CoreWeave's, with a significant shareholder already opposing the deal despite CoreWeave's CEO affirming no sweetening of the offer. The upcoming October 30th shareholder vote is poised to provide critical insight into current AI market valuations and investor expectations for future transactions.

Analysis

Institutional Shareholder Services (ISS) has recommended Core Scientific (CORZ) shareholders reject CoreWeave's (CRWV) proposed $9 billion all-stock acquisition, asserting that CORZ is currently undervalued. This assessment stems from a heightened market appetite for AI-related investments since the initial July offer, which has driven Core Scientific's stock higher. Following the ISS recommendation, Core Scientific shares rose nearly 3%, while CoreWeave's stock declined by approximately 3%.

CoreWeave's CEO, Michael Intrator, has firmly stated that the company will not sweeten its offer, maintaining a fixed valuation for the acquisition. This rigid stance, coupled with explicit opposition from a significant shareholder, Two Seas Capital, which holds a 6.2% stake in CORZ, suggests a high probability of the deal failing at the upcoming October 30th shareholder vote.

The impending vote serves as a critical barometer for current AI technology valuations and investor expectations for future transactions within the sector. Should the deal be rejected, CoreWeave would incur a 4% breakup fee from the July merger agreement, potentially impacting its capital allocation and future M&A strategy.

Key Decisions for Investors

• Investors should closely monitor the October 30th Core Scientific shareholder vote as a key indicator of AI sector valuation sentiment and M&A dynamics.
• Evaluate CoreWeave's strategic options and potential for alternative growth initiatives if the current acquisition fails, considering the negative market reaction and CEO's firm stance.
• Assess Core Scientific's standalone valuation and potential for revised offers or strategic alternatives given the market's perceived undervaluation and positive share price reaction.